Anticancer Drug-Induced Capillary Leak Syndrome

Area of Science:

• Oncology
• Pharmacology
• Pathophysiology

Background:

• Capillary leak syndrome (CLS) is characterized by increased capillary permeability, leading to plasma leakage into tissues.
• Clinical manifestations include hypotension, edema, and elevated hematocrit, with severe cases progressing to shock and death.
• While idiopathic systemic CLS (SCLS) is a classic form, adverse drug reactions are increasingly recognized causes.

Purpose of the Study:

• To review the role of oncologic drugs in causing capillary leak syndrome.
• To identify specific anticancer agents implicated in drug-induced CLS.
• To highlight the significance of monoclonal antibodies, growth factors, and chemotherapy agents in this context.

Main Methods:

• Literature review focusing on adverse drug reactions and capillary leak syndrome.
• Analysis of case reports and clinical studies related to chemotherapy-induced CLS.
• Examination of the mechanisms by which oncologic drugs affect capillary permeability.

Main Results:

• Anticancer drugs are significant contributors to drug-induced capillary leak syndrome.
• Gemcitabine, therapeutic growth factors, and monoclonal antibodies (mAbs) are identified as key culprits.
• These agents can trigger CLS through various mechanisms affecting vascular integrity.

Conclusions:

• Anticancer drug-induced CLS is a critical adverse event that requires clinical awareness.
• Oncologic agents, particularly mAbs and gemcitabine, represent a growing concern for CLS development.
• Further research is needed to elucidate precise mechanisms and develop preventative strategies.